By Robert King
Rural hospitals are struggling to find larger facilities to take care of patients that need more complex care as COVID-19 surges across the country.
read more
By Ben Adams
Johnson & Johnson is confident that it has a one-dose knockout vaccine that can protect against COVID-19, but it’s now starting a late-stage two-dose test just in case.
read more
By Eric Sagonowsky
A week after Pfizer posted impressive early coronavirus vaccine efficacy numbers, Moderna took the spotlight early Monday with impressive findings of its own. But separate from its big announcement, the mRNA biotech said its vaccine can be kept at refrigerated temperatures for 30 days, reducing hurdles for a potential large-scale rollout.
read more
By Eric Sagonowsky
With mRNA-based coronavirus vaccines from Pfizer and Moderna showing promise in efficacy studies, another company working on a mid-stage mRNA candidate has inked a large supply deal with the European Union. CureVac, a German biotech, has agreed to supply the bloc with 225 million doses initially, with an option for another 180 million doses, Reuters reports.
read more
By Robert King
Premier Inc. and 34 health systems have joined up with DeRoyal to create a new joint venture that will make isolation gowns in an effort to move personal protective equipment manufacturing to the U.S.
read more
By Robert King
CommonSpirit Health has posted a $167 million profit in the latest quarter as the health system's patient volumes continue to rebound.
read more
By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner
The EU is in line for 405 million CureVac vaccine doses. Pfizer and Moderna's shot data shouldn't lead to pandemic complacency, WHO warned—though the drugmakers' shots could help control the pandemic in 2021, a former FDA commissioner said. Plus, some states are scrambling for ultra-cold freezers while others establish their own vaccine review panels.
read more
By Eric Sagonowsky
As COVID-19 case counts reach previously unseen highs and vaccines show more promise than ever, the coronavirus team assembled by President-elect Joe Biden is planning to meet with vaccine developers this week. Still, the transition process is getting off to a rocky start.
read more
